<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00537667</url>
  </required_header>
  <id_info>
    <org_study_id>20000211</org_study_id>
    <nct_id>NCT00537667</nct_id>
  </id_info>
  <brief_title>The SPECTRA Study</brief_title>
  <official_title>A Single Centre, Open-Label, Randomised, Study to Evaluate the Effect of Anakinra (r-metHuIL-1ra) Alone and in Combination With PEGylated Recombinant Methionyl Human Soluble Tumour Necrosis Factor Receptor Type I (PEG sTNF-RI) on Synovial Inflammation in Subjects With Rheumatoid Arthritis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swedish Orphan Biovitrum</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare IL-1ra and the combination of IL-1ra and PEGsTNF-RI&#xD;
      with respect to their ability to reduce inflammation and bone and cartilage destruction in&#xD;
      the synovium of subjects with rheumatoid arthritis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The safety profile of combination therapy became unacceptable.&#xD;
  </why_stopped>
  <start_date>August 2001</start_date>
  <completion_date type="Actual">June 2003</completion_date>
  <primary_completion_date type="Actual">March 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary efficacy endpoint is the change from baseline at weeks 4, 26 and 52 in levels of select markers of inflammation (CD3 and CD 68) and destruction (MMP-1 and TIMP-1) in the synovium</measure>
    <time_frame>up to 52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary safety endpoint is the crude and exposure adjusted subject incidence and nature, frequency, severity, relationship to treatment, and outcome of all adverse events</measure>
    <time_frame>up to 52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary efficacy endpoints are change from baseline at week 4 and 52 in selected markers of bone and cartilage degradation and inflammation</measure>
    <time_frame>up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary safety endpoints are changes from baseline in laboratory parameters</measure>
    <time_frame>up to 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>anakinra</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>anakinra and PEGsTNF-R1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anakinra</intervention_name>
    <description>anakinra</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anakinra and PEG sTNF-R1</intervention_name>
    <description>anakinra and PEG sTNF-R1</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with RA as determined by American College of Rheumatology (ACR) criteria&#xD;
             (Appendix C)&#xD;
&#xD;
          -  Disease duration of no less than 12 weeks of diagnosis confirmed by physician and&#xD;
             source documentation&#xD;
&#xD;
          -  Disease duration &lt; 10 years&#xD;
&#xD;
          -  Active RA at baseline as defined by a minimum of 6 or more swollen joints and 9 or&#xD;
             more tender/painful joints (based on a 66/68-joint count excluding distal&#xD;
             interphalangeal joints) at screening and baseline,&#xD;
&#xD;
        And&#xD;
&#xD;
          -  C-reactive protein (CRP) &gt; 2 mg/dL at screening.&#xD;
&#xD;
          -  Have active clinical synovitis in the knee as determined by the investigator based on&#xD;
             clinical evaluation&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Men or non-pregnant (negative serum HCG at screening unless surgically sterile or&#xD;
             postmenopausal), non-breast-feeding women may be enrolled. Females of childbearing&#xD;
             potential and males must use adequate contraceptive precautions as determined by the&#xD;
             principal investigator.&#xD;
&#xD;
          -  Subjects that have taken any DMARD for less than 3 months must not have taken DMARDs&#xD;
             within 4 weeks prior to screening. Subjects that have taken any DMARD for longer than&#xD;
             3 months must not have taken DMARDs within 6 months of screening.&#xD;
&#xD;
          -  Subject's doses of NSAIDs and oral corticosteroids (10 mg/day of prednisone or&#xD;
             equivalent) must have been kept stable for 4 weeks before screening&#xD;
&#xD;
          -  Subjects must not have had intrarticular injections in the joint that will be&#xD;
             arthroscoped for at least 3 months prior to screening.&#xD;
&#xD;
        Before any study specific procedure or screening is done, the subject or legally acceptable&#xD;
        representative must give informed consent for participation in the study (see Section&#xD;
        12.2). Before buccal smears and blood samples are taken for genetic testing, the subject or&#xD;
        legally acceptable representative must give informed consent for use of those samples for&#xD;
        genetic testing (see Section 12.2).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ACR functional class IV or American Rheumatology Association anatomical stage IV (see&#xD;
             Appendix C)&#xD;
&#xD;
          -  Disease duration &gt;10 years&#xD;
&#xD;
          -  Diagnosed with the following:&#xD;
&#xD;
        Felty's syndrome&#xD;
&#xD;
        Advanced or uncontrolled Diabetes Mellitus (defined as: HbA1c &gt; 8%, peripheral neuropathy,&#xD;
        renal/retinal involvement, or vascular disorders)&#xD;
&#xD;
        Malignancy, other than basal cell carcinoma of the skin or in situ carcinoma of the cervix,&#xD;
        within the past five years&#xD;
&#xD;
        Any other major chronic inflammatory disease or syndrome (e.g., psoriatic arthritis,&#xD;
        spondyloarthropathy, inflammatory bowel disease, fibromyalgia that required treatment in&#xD;
        the last year)&#xD;
&#xD;
          -  Any uncontrolled, clinically significant systemic disease&#xD;
&#xD;
          -  Pre-existing or recent onset central nervous system demyelinating disorders&#xD;
&#xD;
          -  Significant hematologic abnormalities&#xD;
&#xD;
          -  A history of drug or alcohol abuse within the previous 24 weeks&#xD;
&#xD;
          -  Known to be hepatitis B surface antigen, hepatitis C virus or Human Immunodeficiency&#xD;
             Virus positive&#xD;
&#xD;
          -  Any disorder that compromises ability to give informed consent for participation in&#xD;
             this study&#xD;
&#xD;
          -  Is expected to require a major surgical operation while on study that would interfere&#xD;
             with the collection of the required assessments.&#xD;
&#xD;
          -  Has an infection requiring systemic anti-infective therapy, open wounds, or has&#xD;
             developed frequent acute or chronic infections during the past 12 weeks.&#xD;
&#xD;
          -  Prior active tuberculosis.&#xD;
&#xD;
          -  Total white blood cell count &lt; 3.5 x 109/L at screening&#xD;
&#xD;
          -  Neutrophil count of &lt; 2.5 x 109/L at screening&#xD;
&#xD;
          -  Platelet count of &lt; 125 x 109/L at screening&#xD;
&#xD;
          -  Hemoglobin &lt; 8.0 g/dL at screening&#xD;
&#xD;
          -  Abnormal liver function tests (AST/ALT &gt; 1.5 x the upper limits of normal) at&#xD;
             screening&#xD;
&#xD;
          -  Abnormal renal function (serum creatinine &gt; 1.5 x the upper limits of normal) at&#xD;
             screening&#xD;
&#xD;
          -  Prior treatment with any protein-based TNF inhibitor (e.g. etanercept, infliximab, PEG&#xD;
             sTNF-RI, D2E7)&#xD;
&#xD;
          -  Prior treatment with anakinra&#xD;
&#xD;
          -  Receiving or has received any investigational drug within the previous 16 weeks or&#xD;
             within at least 5 half-lives of any investigational drug, whichever is greater (or is&#xD;
             currently using an investigational device)&#xD;
&#xD;
          -  Received any intra-articular injections (e.g.. corticosteroids, hyaluronate&#xD;
             preparations) or systemic corticosteroid injections within 4 weeks before the&#xD;
             screening visit&#xD;
&#xD;
          -  Requires analgesia other than paracetamol, NSAIDs, codeine, oxycodone, propoxyphene,&#xD;
             tramadol, hydrocodone, or the combinations of these products (or equivalents)&#xD;
&#xD;
          -  Subject (men or women of childbearing potential) is not using adequate contraceptive&#xD;
             precautions as determined by the principal investigator&#xD;
&#xD;
          -  Known allergy to E coli-derived products&#xD;
&#xD;
          -  Not available for follow-up assessments&#xD;
&#xD;
          -  Concerns for the subject's compliance with the protocol procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://download.veritasmedicine.com/REGFILES/amgen/Amgen_results_disclaimer.pdf</url>
    <description>Notice regarding posted summaries of trial results</description>
  </link>
  <link>
    <url>http://download.veritasmedicine.com/REGFILES/amgen/08D_FDAMA_113_Posting_Summary_25_IL-1RA_20000211.pdf</url>
    <description>To access clinical trial results information click on this link</description>
  </link>
  <link>
    <url>http://www.kineretrx.com/</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>September 27, 2007</study_first_submitted>
  <study_first_submitted_qc>September 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2007</study_first_posted>
  <last_update_submitted>November 25, 2009</last_update_submitted>
  <last_update_submitted_qc>November 25, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2009</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>IL-1ra</keyword>
  <keyword>PEG sTNF-RI</keyword>
  <keyword>Synovial biopsy</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Bone and Cartilage Destruction</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

